Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure

Circulation: Heart Failure

Volumn 3, Issue 4, 2010, Pages 537-546

  Middlekauff, Holly R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INFLIXIMAB; LOSARTAN; CALCIUM;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL FEATURE; DOWN REGULATION; EXERCISE; HEART FAILURE; HUMAN; INFLAMMATION; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MUSCLE CONTRACTION; MUSCLE EXCITATION; MYOPATHY; NONHUMAN; OXIDATION; OXYGEN TRANSPORT; PRIORITY JOURNAL; REST; SKELETAL MUSCLE; STRESS; ADAPTATION; ADRENERGIC SYSTEM; ANIMAL; EXERCISE TOLERANCE; FEMALE; HEART PACING; HEMODYNAMICS; KINESIOTHERAPY; MALE; METABOLISM; METHODOLOGY; MUSCLE DISEASE; MUSCLE WEAKNESS; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CALCIUM; CARDIAC PACING, ARTIFICIAL; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DISEASES; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 77955496945     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.903773     Document Type: Article

References (72)

1. Vantura-Clapier R, De Sousa E, Veksler V. Metabolic myopathy in HF. N Physiol Sci. 2002;17:191-196.
2. Duscha B, Schulze PC, Robbins JL, Forman DE. Implications of chronic HF on peripheral vasculature and skeletal muscle before and after exercise training. Heart Fail Rev. 2008;13:21-37.
3. Troosters T, Gosselink R, Decramer M. COPD and chronic HF: two muscle diseases? J Cardiopulm Rehabil. 2004;24:137-145.
4. Sinoway LI, Li J. A perspective on the muscle reflex: implications for congestive HF. J Appl Physiol. 2005;99:5-22.
5. Witte KK, Clark AL. Why does chronic HF cause breathlessness and fatigue? Prog Cardiovasc Dis. 2007;49:366-384.
6. Hsia CCW. Coordinated adaptation of oxygen transport in cardiopulmonary disease. Circulation. 2001;104:963-969.
7. Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, Wilson JR. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in HF. Circulation. 1992;85: 1364-1373.
8. Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA, Coats AJ. Skeletal muscle function and its relation to exercise tolerance in chronic HF. J Am Coll Cardiol. 1997;30: 1758-1764.
9. Mancini DM, Coyle E, Coggan A, Beltz J, Ferraro N, Montain S, Wilson JR. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic HF. Circulation. 1989;80:1338-1346.
10. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in chronic HF. Circulation. 1992;85:1751-1759.
11. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term HF. Circulation. 1990; 81:518-527.
12. Schaufelberger M, Eriksson BO, Grimby G, Held P, Swedberg K. Skeletal muscle alterations in patients with chronic HF. Eur Heart J. 1997;18:971-980.
13. Duscha BD, Kraus WE, Keteyian SJ, Sullivan MJ, Green HJ, Schachat FH, Pippen AM, Brawner CA, Blank JM, Annex BH. Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic HF independent of other peripheral alterations. J Am Coll Cardiol. 1999;33:1956-1963.
14. Massie B, Conway M, Yonge R, Frostick S, Ledingham J, Sleight P, Radda G, Rajagopalan B. Skeletal muscle metabolism in patients with congestive HF: relation to clinical severity and blood flow. Circulation. 1987;76:1009-1019.
15. Massie BM, Simonini A, Sahgal P, Wells L, Dudley GA. Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive HF. J Am Coll Cardiol. 1996;27: 140-145.
16. Mettauer B, Zoll J, Sanchez H, Lampert E, Ribera F, Veksler V, Bigard X, Mateo P, Epailly E, Lonsdorfer J, Ventura-Clapier R. Oxidative capacity of skeletal muscle in HF patients versus sedentary or active control subjects. J Am Coll Cardiol. 2001;38:947-954.
17. Williams AD, Selig S, Hare DL, Hayes A, Krum H, Patterson J, Geerling RH, Toia D, Carey MF. Reduced exercise tolerance in CHF may be related to factors other than impaired skeletal muscle oxidative capacity. J Card Fail. 2004;10:141-148.
18. Lehnart SE. Novel targets for treating heart and muscle disease: stabilizing ryanodine receptors and preventing intracellular calcium leak. Curr Opin Pharmacol. 2007;7:225-232.
19. Bellinger AM, Mongillo M, Marks AR. Stressed out: the skeletal muscle ryanodine receptor as a target of stress. J Clin Invest. 2008;118:445-453.
20. Reiken S, Lacampagne A, Zhou H, Kherani A, Lehnart SE, Ward C, Huang F, Gaburjakova M, Gaburjakova J, Rosemblit N, Warren MS, He K, Yi G, Wang J, Burkhoff D, Vassort G, Marks AR. PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in HF. J Cell Biol. 2003;160: 919-928.
21. Danila CI, Hamilton SL. Phosphorylation of ryanodine receptors. Biol Res. 2004;37:521-525.
22. Periasamy M, Kalyanasundaram A. SERCA pump isoforms: their role in calcium transport and disease. Muscle Nerve. 2007;35:430-442.
23. Hovnanian A. SERCA pumps and human diseases. Subcell Biochem. 2007;45:337-363.
24. Green HJ, Burnett M, Duhamel TA, D'Arsigny C, O'Donnell DE, Webb KA, Ouyang J. Skeletal muscle dysfunction in COPD: a statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med. 1999;159:S1-S40.
25. Weibel ER, Taylor CR, Hoppeler H. The concept of symmorphosis: a testable hypothesis of structure-function relationship. PNAS. 1991;88: 10357-10361.
26. ATS, ERS. Skeletal muscle dysfunction in COPD: a joint statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med. 1999; 159:S1-S40.
27. Adams GR, Vaziri ND. Skeletal muscle dysfunction in chronic renal failure: effects of exercise. Am J Physiol Renal Physiol. 2006;290: F753-F761.
28. Alves MJ, Rondon MU, Santos AC, Dias RG, Barretto AC, Krieger EM, Middlekauff HR, Negrao CE. SNA restrains reflex vasodilatation in HF. Clin Auton Res. 2007;17:364-369.
29. Tsutue H, Ide T, Hayashidani S, Suematsu N, Shiomi T, Wen J, Nakamura K, Ichikawa K, Utsumi H, Takeshita A. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of HF. Circulation. 2001;104:134-136.
30. Muller-Wedan U, Werdan K. Immune modulation by catecholamines: a potential mechanism of cytokine release in HF? Herz. 2000;25:271-273.
31. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic HF. Lancet. 1997;349: 1050-1053.
32. Reid MB, Li YP. Cytokines and oxidative signaling in skeletal muscle. Acta Physiol Scand. 2001;171:225-232.
33. Libera LD, Sabbadini R, Renken C, Ravara B, Sandri M, Betto R, Angelini A, Vescovo G. Apoptosis in the skeletal muscle of rats with HF is associated with increased serum levels of TNF-alpha and sphingosine. J Mol Cell Cardiol. 2001;33:1871-1878.
34. Gielen S, Adams V, Mobius-Winkler S, Linke A, Erbs S, Yu J, Kempf W, Schubert A, Schuler G, Hambrecht R. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic HF. J Am Coll Cardiol. 2003;42:861-868.
35. Larsen AI, Lindal S, Aukrust P, Toft I, Aarsland T, Dickstein K. Effect of exercise training on skeletal muscle fibre characteristics in men with chronic HF: correlation between skeletal muscle alterations, cytokines and exercise capacity. Int J Cardiol. 2002;83:25-32.
36. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe HF. Am J Cardiol. 1997;79:1128-1131.
37. Torre-Amione T, Kapadia S, Benedict CL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the SOLVD. J Am Coll Cardiol. 1996;27:1201-1206.
38. Ostrowski K, Rohde T, Zacho M. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol. 1998;508: 949-953.
39. Baeuerle PA, Baltimore D. NF-kappa-beta: ten years after. Cell. 1996; 87:13-20.
40. Adams V, Jiang H, Yu J, Mobius-Winkler S, Fiehn E, Linke A, Weigl C, Schuler G, Hambrecht R. Apoptosis in skeletal myocytes of patients with chronic HF is associated with exercise intolerance. J Am Coll Cardiol. 1999;33:959-965.
41. Hartling OJ, Trap-Jansen J. Stimulation of beta-adrenoceptors in the exercising human forearm. Clin Physiol. 1982;2:363-371.
42. Stainsby WN, Sumners C. Effects of catecholamines on lactic acid output during progressive working contractions. J Appl Physiol. 1985;59: 1809-1814.
43. Vescovo G, Serfini F, Facchin LL. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis. Heart. 1996;76:337-343.
44. Franssen FM, Wouters EF, Schols AM. The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. 2002;21:1-14.
45. Simonini A, Long CS, Dudley GA, Yue P, McElhinny J, Massie BM. HF in rats causes changes in skeletal muscle morphology and gene expression that are not explained by reduced activity. Circ Res. 1996;79:128-136.
46. Khan MH, Sinoway LI. Muscle reflex control of SNA in HF: the role of exercise conditioning. Heart Fail Rev. 2000;5:87-100.
47. Smith SA, Mitchell JH, Garry MG. The mammalian exercise pressor reflex in health and disease. Exp Physiol. 2005;91:89-102.
48. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in HF: physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747-1762.
49. Clark AL, Poole-Wilson PA, Coats AJS. Exercise limitation in chronic HF: central role of the periphery. J Am Coll Cardiol. 1996;28:1092-1002.
50. Middlekauff HR, Sinoway LI. Point:Counterpoint: Increased mechanoreceptor/ metaboreceptor stimulation explains the exaggerated exercise pressor reflex seen in HF. J Appl Physiol. 2006;102:492-494.
51. Zoll J, Monassier L, Garnier A, N'Guessan B, Mettauer B, Veksler V, Piquard F, Ventura-Calpier R, Geny B. ACE inhibition prevents myocardial infarction-induced skeletal muscle mitochondrial dysfunction. J Appl Physiol. 2006;101:385-391.
52. Vescovo G, Libera LD, Serafini F, Leprotti C, Facchin L, Volterrani M, Cecpmo C, Ambrosio GB. Improved exercise tolerance after losartan and enalapril in HF: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation. 1998;98:1742-1749.
53. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Musclespecific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest. 2005;115:451-458.
54. Libera LD, Ravara B, Gobbo V, Betto DD, Germinario E, Angelini A, Vescovo G. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of carvedilol. J Mol Cell Cardiol. 2005;38: 803-807.
55. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-tosevere HF: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
56. Mann DL, McMurray JJ, Packer M, Swedburg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westhein A, Zannad F, Fleming T. Targeted anti-cytokine therapy in patients with chronic HF: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
57. Gupta D, Palma J, Molina E, Gaughan JP, Long W, Houser S, Macha M. Improved exercise capacity and reduced systemic inflammation after adenoviral-mediated SERCA-2a gene transfer. J Surg Res. 2008;145: 257-265.
58. Khan H, Metra M, Blair JEA, Vogel M, Harinstein ME, Filippatos GS, Sabbah HN, Porchet H, Valentini G, Gheorghiade M. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-KATPase inhibition: a new promising treatment for acute HF syndromes. Heart Fail Rev. 2009;14:277-287.
59. Cittadini A, Saldamarco L, Marr AM, Arco M, Carlomagn G, Imbriaco M, DelForno D, Vigorito C, Merola B, Oliviero U, Fazio S, Sacca L. Growth hormone deficiency in patients with chronic HF and beneficial effects of its correction. J Clin Endocrinol Metab. 2009;94:3329-3336.
60. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GMC. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic HF. J Am Coll Cardiol. 2009;54:919-927.
61. Vilquin JT. Myoblast transplantation: clinical trials and perspectives. Acta Myol. 2005;24:119-127.
62. Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC; for the Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with HF and intra-ventricular conduction delay. N Engl J Med. 2001;344:873-880.
63. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon A, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Messenger J; for the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Investigators and Coordinators. Double-blind, randomized controlled trial of cardiac resynchronization in chronic HF. N Engl J Med. 2002;346: 1845-1853.
64. Grassi G, Vincenti A, Brambilla R, Trevano FQ, Dell'Oro R, Trocino G, Vincenzi A, Mancia G. Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe HF. Hypertension. 2004;44:727-731.
65. Corra U, Mezzani A, Giannuzzi P, Tavazzi L. Chronic heart failurerelated myopathy and exercise training: a developing therapy for HF symptoms. Prog Cardiovasc Dis. 2002;44:157-172.
66. McKelvie RS, Teo KK, McCartney N, Humen D, Montague T, Yusuf S. Effects of exercise training in patients with congestive HF: a critical review. J Am Coll Cardiol. 1995;789-796.
67. Ventura-Clapier R, Mettauer B, Bigard X. Beneficial effects of endurance training on cardiac and skeletal muscle energy metabolism in HF. Cardiovasc Res. 2007;73:10-18.
68. Roveda F, Middlekauff HR, Reis S, De Souza M, Barretto AC, Rondon MUB, Nastari L, Krieger EM, Negrao CE. Effects of exercise training on neurovascular control during exercise in HF patients. J Am Coll Cardiol. 2003;42:854-860.
69. Varin R, Mulder P, Richard V, Tamion F, Devaux C, Henry JP, Lallemand F, Lerebours G, Thuillez C. Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic HF: role of nitric oxide, prostanoids, and oxidant stress. Circulation. 1999;99: 2951-2957.
70. Ennezat PV, Malendowicz SL, Testa M, Colombo PC, Cohen-Solal A, Evans T, LeJemtel TH. Physical training in patients with chronic HF enhances the expression of genes encoding anti-oxidative enzymes. J Am Coll Cardiol. 2001;38:194-198.
71. Coats AJ, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L, Solda PL, Davey P, Ormerod O, Forfar C. Controlled trial of physical training in chronic HF: exercise performance, hemodynamics, ventilation, and autonomic function. Circulation. 1992;85:2119-2131.
72. Gao L, Wang W, Liu D, Zucker IH. Exercise training normalizes sympathetic outflow by central antioxidant mechanisms in rabbits with pacing-induced chronic HF. Circulation. 2007;115:3042-3044.